About
RAFARM is a pharmaceutical company in Greece that develops, manufactures, and supplies complex sterile products, especially ophthalmics and injectables. It serves partners in CDMO, CMO, and out-licensing models, and also sells products in Greece and Cyprus. Its activities are centered at RAFARM Campus in Attica, Greece.
Services
R&D and product development
Designs process-development strategies, evaluates API suppliers, applies QbD, and develops pharmaceutical products in collaboration with customers.
Non-clinical and stability studies
Designs and implements non-clinical in-vitro studies and executes stability studies.
Technology transfer
Provides technology transfer activities as part of development support.
Dossier and registration support
Develops product dossiers and supports registration processes, including upgrading older dossiers to current standards.
Manufacturing
Provides end-to-end contract manufacturing services for ophthalmic and injectable products.
Scale-up and commercial manufacturing
Supports product scale-up in manufacturing and transition from development to commercial scale.
Quality control and quality assurance
Operates quality control and assurance activities across development, production, and distribution under a Quality Management System.
Regulatory affairs
Monitors pharmaceutical legislation, advises on legal and scientific requirements, and secures and maintains marketing authorizations.
10 more services
- Out-licensing and supply
- B2C commercial supply in Greece and Cyprus
- Development and production of sterile ophthalmic products
- Development and production of complex injectable products
- Value Added Medicines development
- Process development
- Non-clinical study support
- Stability studies
- Product dossier development
- Manufacturing problem solving
Capabilities
- Assays and studies
- Process development
- Stability studies
- Non-clinical in-vitro studies
- Quality control
- Quality assurance
- In-vitro studies
- Scale and capacity
- Annual Capacity (1 shift): 300,000,000 tablets
- Annual Capacity (1 shift): 15,000,000 vials
- Annual Capacity (1 shift): 10,000,000 ampoules
- Annual Capacity (1 shift): 40,000,000 units of ophthalmic products
- >1,350 own development pharmaceutical products
- >100 products with regulatory approval worldwide
- 12 ANDA approvals from FDA
- Therapeutic areas
- Ophthalmology
- Glaucoma
- Ocular hypertension
- Inflammation and pain after cataract surgery
- Inflammatory conditions of the anterior segment of the eye
- Anterior uveitis
- Antiallergic
- Bacterial external ocular infections
Instruments and platforms
- BMS – Building Management System
Modalities and species
- Modalities
- Small molecule
Details
- Type
- CDMO
- Quality
- GMP (Good Manufacturing Practice) (manufacturing facilities) · cGMPs (quality management system) · EU GMP (successful inspections) · US FDA (successful inspections) · Russia FMBA (successful inspections) · Canada HC (successful inspections) · Taiwan authorities (successful inspections) · Tunisian authorities (successful inspections) · Saudi Arabia authorities (successful inspections) · Korea authorities (successful inspections) · Greek National Organization for medicine (successful inspections)
- Based in
- Athens, Greece
- Sites
- Attica, Greece · Neo Psychiko, Greece
- Serves
- Worldwide, USA, Canada, Europe, Middle East, Greece, Cyprus